AstraZeneca and Takeda Pharmaceutical have entered into an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).
Forma Therapeutics and Celgene announced an innovative R&D partnership in 2014 to pursue ground-breaking medicines in oncology and other therapeutic areas.
Biopharmaceutical firm Gilead Sciences has agreed to acquire US-based Kite Pharma for around $11.9bn.
Celgene has revised the terms of its immuno-oncology collaboration with Sutro Biopharma, which was established in 2014.
Dermira has signed a licensing agreement with Roche to secure exclusive rights to lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications.
Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.
The Association of the British Pharmaceutical Industry (ABPI) has applied for judicial review over new procedures that restrict access to cost-effective medicines.
Pfizer has broke ground on a research and development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield in the US state of Missouri.
Eli Lilly and Company has completed the $90m expansion of its biotechnology center in San Diego, California, US.
Bristol-Myers Squibb has agreed to divest its small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland, to South Korea based SK Biotek, a subsidiary of SK Holdings.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.